CORONA Remedies Posts Strong Financial Results, Reports 17.3% Revenue Growth and 33.4% PAT Increase in FY26

CORONA Remedies Posts Strong Financial Results, Reports 17.3% Revenue Growth and 33.4% PAT Increase in FY26​

Ahmedabad | CORONA Remedies Limited, a leading India-focused branded pharmaceutical company, announced its audited financial results for the fourth quarter of fiscal year 2026 (Q4FY26) and the full fiscal year 2026 (FY26). The company reported robust financial performance, driven by concentrated brand-building initiatives, portfolio expansion, and strong operational efficiencies.

The financial results showcase significant year-over-year (YoY) growth, with revenue from operations achieving 20.2% growth in Q4FY26 and 17.3% growth for the full fiscal year 2026. Profit After Tax 1 (PAT 1) saw marked increases of 43.7% in Q4FY26 and 33.4% in FY26, supported by improved operational leverage and cost optimization.

Financial Performance Snapshot​

The company’s financial performance for the two quarters is detailed in the following table:

Strategic Growth and Market Expansion​

CORONA Remedies highlighted several key strategic achievements contributing to the strong financial performance. The company successfully entered the Povidone Iodine market through the acquisition of WOKADINE, an acquisition funded using internal accruals.

Furthermore, the company bolstered its addressable market through portfolio expansion initiatives. Key brands, including fostine R and Menodac, were relaunched under Women's Health Therapeutics, while Noklot was introduced in the Cardiovascular segment. Addressing specialized medical needs, a dedicated team was also established to focus on the high-growth infertility segment.

On the brand strength front, CORONA Remedies achieved a milestone by having two of its brands cross the ₹100 Cr Market Annual Turnover (MAT) revenue mark by March 2026. In terms of market standing, the company improved its industry ranking to 27th from 32nd over the last three years.

Management Commentary​

Mr. Nirav K. Mehta, Managing Director and CEO of CORONA Remedies Limited, commented on the results, stating that FY26 was a strong year marked by consistent revenue growth and enhanced operational efficiency.

He noted, "Our strategic focus on brand building, specialty segments like biosimilars and infertility, and portfolio expansion through acquisitions continues to strengthen our competitive positioning. With strategic initiatives like the acquisition of WOKADINE and securing global accreditations, we are well-positioned to drive sustainable growth in years to come."

Operationally, the company reported that chronic therapies remained a strong contributor, accounting for approximately 72.3% of the total Revenue in Q4FY26 and 71.9% in FY26. Additionally, the EAEU-GMP certification enables the company’s entry into markets including Russia, Belarus, Kazakhstan, Armenia, and Kyrgyzstan.

CORONA Stock Price Movement​

Today, CORONA Remedies Limited shares rallied, settling at ₹1755.8 after gaining 3.08% in post-market trading. The stock peaked at its 52-week high of ₹1807.4 during the session, supported by a strong trading volume of 47,515 shares.